P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer

Published:2014-12 Issue:1 Volume:355 Page:54-60
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Shariat Sheida,Badiee Ali,Jalali Seyed Amir,Mansourian Mercedeh,Yazdani Mona,Mortazavi Seyed Alireza,Jaafari Mahmoud Reza

Funder

Shahid Beheshti University of Medical Sciences

Mashhad University of Medical Sciences

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Breakthrough of the year 2013. Cancer immunotherapy;Couzin-Frankel;Science,2013

2. Eradication of established tumors by CD8+ T cell adoptive immunotherapy;Hanson;Immunity,2000

3. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy;Matsui;Int. Immunol,2003

4. Decisions about dendritic cells: past, present, and future;Steinman;Annu. Rev. Immunol,2012

5. Human dendritic cell subsets in vaccination;Palucka;Curr. Opin. Immunol,2013

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of chitosan nanoparticle as a carrier for systemic acquired resistance (SAR)-inducing recombinant protein: A preliminary study;Asia Pacific Journal of Molecular Biology and Biotechnology;2024-02-17

2. Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model;2024-02-14

3. Canine mammary carcinoma: current therapeutic targets and future perspectives – a review;Annals of Animal Science;2023-07-01

4. Nanomaterials in Cancer Immunotherapy: A Spotlight on Breast Cancer;Science of Advanced Materials;2023-03-01

5. Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection;Biomedicine & Pharmacotherapy;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3